After seven years of research conducted at SUNY Upstate Medical University and Penn State, there is a new saliva test designed to aid in the diagnosis of autism. The scientists behind the test, as well as the company behind development, called Quadrant Biosciences Inc., hope this test will help clinical professionals detect autism faster to expedite services for children with autism.
This saliva test, called Clarifi ASD, is now available in 49 states, excluding New York. It has been approved by the Centers for Medicare and Medicaid Services and is expected to get Health Department approval by 2020, which will make the saliva test available in New York as well.
The test must be ordered and administered by a health care professional. This diagnostic aid currently costs $989 and is not yet covered by insurance, although the National Institutes of Health is working with Quadrant Biosciences to get the test covered by Medicaid and other private insurers in the future.
Quadrant Biosciences Inc. is a collaborative effort led by company founder and Chief Executive Officer Richard Uhlig. The management team has been carefully balanced to facilitate the ongoing development, testing, and distribution of products, and includes expertise in engineering, Food & Drug Administration regulatory compliance, production, marketing, and sales. The advisory board comprises highly regarded medical experts and data scientists.
This was reported by ASDLinks on December 30, 2019.
Contact information: Quadrant Biosciences Inc., 505 Irving Avenue, Suite 3100 AB, Syracuse, New York 13210; 315-614-2325; Website: www.quadrantbiosciences.com